| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce... |
| 07/05/2023 |
4
| Alleva Lawrence M (Director) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 22,762 options to buy
@ $3.12, valued at
$71k
|
|
| 07/05/2023 |
4
| West Linda (Director) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 23,382 options to buy
@ $3.12, valued at
$73k
|
|
| 06/28/2023 |
SC 13G/A
| Novo Holdings A/S reports a 4.9% stake in Galera Therapeutics, Inc. |
| 06/16/2023 |
4
| POWELL MICHAEL (Director) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 64,000 options to buy
@ $3.27, valued at
$209.3k
|
|
| 06/16/2023 |
4
| West Linda (Director) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 48,000 options to buy
@ $3.27, valued at
$157k
|
|
| 06/16/2023 |
4
| LOKAY KEVIN G (Director) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 48,000 options to buy
@ $3.27, valued at
$157k
|
|
| 06/16/2023 |
4
| Cunningham Emmett (Director) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 48,000 options to buy
@ $3.27, valued at
$157k
|
|
| 06/16/2023 |
4
| Alleva Lawrence M (Director) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 48,000 options to buy
@ $3.27, valued at
$157k
|
|
| 05/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/14/2023 |
4
| Sorensen Mel (President and CEO) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Bought 100,000 shares
@ $1.6812, valued at
$168.1k
|
|
| 03/14/2023 |
4
| Degnan Chris (CFO) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $1.9593, valued at
$19.6k
|
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/08/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/08/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
4
| Beardsley Robert A (COO) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 135,000 options to buy
@ $1.78, valued at
$240.3k
|
|
| 02/28/2023 |
4
| Sorensen Mel (President and CEO) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 440,000 options to buy
@ $1.78, valued at
$783.2k
|
|
| 02/28/2023 |
4
| Degnan Chris (CFO) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 185,000 options to buy
@ $1.78, valued at
$329.3k
|
|
| 02/28/2023 |
4
| Kennedy Eugene P. (Chief Medical Officer) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 55,000 options to buy
@ $1.78, valued at
$97.9k
|
|
| 02/28/2023 |
4
| Bachleda Mark (Chief Commercial Officer) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 135,000 options to buy
@ $1.78, valued at
$240.3k
|
|
| 02/28/2023 |
4
| Stacey Jennifer Evans (See Remarks) has filed a Form 4 on Galera Therapeutics, Inc.|
Txns:
| Granted 135,000 options to buy
@ $1.78, valued at
$240.3k
|
|
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/09/2023 |
SC 13D
| Blackstone Holdings I/II GP L.L.C. reports a 7.8% stake in Galera Therapeutics, Inc. |
| 01/25/2023 |
8-K
| Other Events Interactive Data |
| 12/12/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/09/2022 |
8-K
| Quarterly results |
|